LEVI-04 (neutrophin-3 inhibitor presented as #ACR24 late-breaker in knee OA) more good efficacy data, no rapidly progressive OA safety signal. For us clinicians: impressive impact size, esp relative to alternatives. Finally, something that works?? #EULAR2025 OP0374 @RheumNow https://t.co/iVdlwyaqrv